GPE	India
NOW	’s
AND	Patently
ORG	Wise
DEF	Decision
CON	NEW YORK
AND	–
DEF	The
GPO	Indian
ORG	Supreme
ORG	Court
NOW	’s
CON	refusal
SUB	to
EXS	uphold
DEF	the
CON	patent
REL	on
GEO	Gleevec
EQU	,
DEF	the
IST	blockbuster
CON	cancer
CON	drug
EXS	developed
REL	by
DEF	the
GPO	Swiss
REL	pharmaceutical
IST	giant
GEO	Novartis
NIL	,
NOW	is
IST	good
CON	news
REL	for
QUC	many
AND	of
DST	those
REL	in
GPE	India
EXS	suffering
REL	from
CON	cancer
NIL	.
IMP	If
ALT	other
EXG	developing
CON	countries
EXS	follow
GPE	India
NOW	’s
CON	example
NIL	,
PRO	it
FUT	will
EXS	be
IST	good
CON	news
AND	elsewhere
NIL	,
IST	too
AND	:
IST	more
CON	money
POS	could
EXS	be
EXS	devoted
REL	to
ALT	other
CON	needs
NIL	,
SUB	whether
EXG	fighting
REL	AIDS
NIL	,
EXG	providing
CON	education
NIL	,
DIS	or
EXG	making
CON	investments
SUB	that
EXS	enable
CON	growth
AND	and
CON	poverty
CON	reduction
NIL	.
AND	But
DEF	the
GPO	Indian
CON	decision
ALT	also
NOW	means
IST	less
CON	money
REL	for
DEF	the
IST	big
IST	multinational
REL	pharmaceutical
CON	companies
NIL	.
NOT	Not
INT	surprisingly
NIL	,
PRX	this
NOW	has
EXS	led
REL	to
DIS	an
EXS	overwrought
CON	response
REL	from
PRO	them
AND	and
HAS	their
CON	lobbyists
AND	:
DEF	the
CON	ruling
NIL	,
PRO	they
CON	allege
NIL	,
NOW	destroys
DEF	the
CON	incentive
SUB	to
EXS	innovate
NIL	,
COO	and
IST	thus
FUT	will
EXS	deal
DIS	a
IST	serious
CON	blow
REL	to
IST	public
CON	health
IST	globally
NIL	.
PRX	These
CON	claims
NOW	are
IST	wildly
EXS	overstated
NIL	.
REL	In
DEF	both
IST	economic
AND	and
IST	social-policy
CON	terms
NIL	,
DEF	the
GPO	Indian
CON	court
AND	’s
CON	decision
NOW	makes
IST	good
CON	sense
NIL	.
AND	Moreover
NIL	,
PRO	it
NOW	is
XCL	only
DIS	a
IST	localized
CON	effort
REL	at
CON	rebalancing
DIS	a
IST	global
CON	intellectual-property
SUB	(
ORG	IP
NIL	)
CON	regime
AND	that
NOW	is
EXS	tilted
IST	heavily
AND	toward
IST	pharmaceutical
CON	interests
REL	at
DEF	the
CON	expense
AND	of
IST	social
CON	welfare
NIL	.
AND	Indeed
NIL	,
UNK	there
NOW	is
DIS	a
EXG	growing
CON	consensus
AND	among
CON	economists
AND	that
DEF	the
IST	current
CON	IP
CON	regime
IST	actually
CON	stifles
CON	innovation
NIL	.
DEF	The
CON	impact
AND	of
IST	strong
CON	IP
CON	protection
REL	on
IST	social
CON	welfare
NOW	has
IST	long
PFT	been
EXS	considered
IST	ambiguous
NIL	.
DEF	The
CON	promise
AND	of
CON	monopoly
CON	rights
POS	can
EXS	spur
CON	innovation
SUB	(
SUB	though
DEF	the
INT	most
IST	important
CON	discoveries
NIL	,
AND	like
DST	that
AND	of
GEO	DNA
NIL	,
IST	typically
ENS	occur
AND	within
CON	universities
AND	and
CON	government-sponsored
CON	research
CON	labs
NIL	,
COO	and
EXS	depend
REL	on
ALT	other
CON	incentives
NIL	)
NIL	.
AND	But
UNK	there
IST	often
NOW	are
IST	serious
CON	costs
AND	as
IST	well
AND	:
MOR	higher
CON	prices
REL	for
CON	consumers
NIL	,
DEF	the
EXG	dampening
CON	effect
REL	on
IST	further
CON	innovation
AND	of
EXG	reducing
CON	access
REL	to
CON	knowledge
NIL	,
AND	and
NIL	,
REL	in
DEF	the
CON	case
AND	of
EXG	life-saving
CON	drugs
NIL	,
CON	death
REL	for
AND	all
AND	who
NOW	are
IST	unable
SUB	to
EXS	afford
DEF	the
CON	innovation
AND	that
POS	could
EXT	have
EXS	saved
PRO	them
NIL	.
DEF	The
CON	weight
EXS	given
REL	to
AND	each
AND	of
PRX	these
CON	factors
NOW	depends
REL	on
CON	circumstances
AND	and
CON	priorities
NIL	,
COO	and
NEC	should
EXS	vary
REL	by
CON	country
AND	and
CON	time
NIL	.
ORG	Advanced
IST	industrialized
CON	countries
REL	in
MOR	earlier
CON	stages
AND	of
HAS	their
CON	development
EPS	benefited
REL	from
IST	faster
IST	economic
CON	growth
AND	and
MOR	greater
IST	social
CON	welfare
REL	by
IST	explicitly
EXG	adopting
MOR	weaker
CON	IP
CON	protection
AND	than
NOW	is
EXS	demanded
AND	of
EXG	developing
CON	countries
NOW	today
NIL	.
AND	Even
REL	in
DEF	the
CON	United States
NIL	,
UNK	there
NOW	is
EXG	growing
SUB	concern
SUB	that
IST	so-called
IST	hold-up
CON	patents
AND	and
CON	me-too
CON	patents
NIL	–
COO	and
DEF	the
IST	sheer
CON	thicket
AND	of
CON	patents
NIL	,
REL	in
UNK	which
AND	any
CON	innovation
NOW	is
IST	likely
SUB	to
EXS	become
UNK	entangled
REL	in
DIS	someone
AND	else
HAS	’s
CON	IP
CON	claims
NIL	–
NOW	are
EXS	diverting
IST	scarce
CON	research
CON	resources
IST	away
REL	from
HAS	their
INT	most
IST	productive
CON	uses
NIL	.
GPE	India
NOW	represents
IST	only
INT	about
QUC	1-2
UOM	%
AND	of
DEF	the
IST	global
IST	pharmaceutical
CON	market
NIL	.
